The researchers have found that a drug commonly used to treat type 2 diabetes can potentially be used in the treatment of autoimmune disorders.
The researchers have found that the drug, canagliflozin (also known as Invokana), could be used to treat autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus as it targets T-cells, which form an essential component of the immune system. Canagliflozin is a drug that controls blood sugar levels in people with type 2 diabetes, however researchers have found an unexpected role for the drug involving the human immune system.
Existing research has reported that targeting T-cell metabolism in autoimmunity can lead to therapeutic benefits. T-cells are a type of white blood cell that help the body fight infections and diseases, but in autoimmune diseases they have been observed to attack healthy tissues.
The new study, funded published in the journal Cell Metabolism, found that canagliflozin dampens down T-cell activation, suggesting that the drug could be repurposed as a treatment for T-cell driven autoimmunity.
The senior author who led the study said: “Our findings are significant as they provide the foundation for the clinical development of canagliflozin for the treatment of certain autoimmune diseases. As the drug is already widely used and has a known safety profile in humans, it could potentially reach clinic quicker than any new drugs developed and bring valuable benefits more swiftly to patients with autoimmune disorders.”
The first author and postdoctoral researcher said: “Identifying new roles for drugs that are currently being used in other disease settings is an exciting area of research. Given that our research primarily targets the metabolism of immune cells, we hope that the potential therapeutic benefits of our findings are applicable to a wide range of conditions.”
The researchers are hopeful that canagliflozin will enter a clinical trial to treat certain autoimmune disorders in the future.
https://www.cell.com/cell-metabolism/fulltext/S1550-4131(23)00178-X
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fcanagliflozin-impairs-t&filter=22
Type 2 diabetes drug could treat autoimmune disorders
- 1,328 views
- Added
Latest News
Mechanism of sugar signalin…
By newseditor
Posted 19 May
How does the brain turn wav…
By newseditor
Posted 19 May
A trial HIV vaccine trigger…
By newseditor
Posted 19 May
AI to predict DNA methylati…
By newseditor
Posted 19 May
Hyperactive platelets from…
By newseditor
Posted 19 May
Other Top Stories
Understanding workings of Parkinson's linked proteins
Read more
Human brains transmit information via multiple parallel pathways
Read more
New coding mechanism that transfers information from perception to…
Read more
Soft robotic apparel to avert freezing of gait in Parkinson's disease
Read more
A NICER approach to genome editing
Read more
Protocols
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Methods for making and obse…
By newseditor
Posted 15 May
Mime-seq 2.0: a method to s…
By newseditor
Posted 13 May
Improved detection of DNA r…
By newseditor
Posted 09 May
Single-cell adhesive profil…
By newseditor
Posted 07 May
Publications
Molecular mechanism of treh…
By newseditor
Posted 19 May
Hue selectivity from recurr…
By newseditor
Posted 19 May
Vaccine induction of hetero…
By newseditor
Posted 19 May
Brain border-associated mac…
By newseditor
Posted 19 May
Inhibition of fatty acid up…
By newseditor
Posted 19 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar